Sweden’s Sobi has announced that the European Commission (EC) has approved Aspaveli (pegcetacoplan) for adults and ...

Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 ...

Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of ...

Blood pressure medicines are among the most commonly prescribed drugs in the world. Millions of people take them every day to ...

It doesn’t take a rocket ― er, dick scientist ― to know that it’s not just whiskey that causes whiskey dick. Vodka drinkers ...

Exposure to extreme cold conditions coupled with pollution increases the risk of preterm births and a rise in blood pressure ...

Exposure to extreme cold conditions coupled with pollution increases the risk of preterm births and a rise in blood pressure ...

Sodium-glucose cotransporter 2 inhibitors (eg, dapagliflozin) are understudied in kidney transplant recipients. A trial attempted to fill this knowledge gap.

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN ...

IgA nephropathy is a type of kidney disease that is typically treated with various medicines and lifestyle changes. Learn more about IgA nephropathy treatment here.

Medically reviewed by Matthew Wosnitzer, MD Signs and symptoms of IgA nephropathy vary among individuals and may not manifest ...